Invitrogen: New Herceptin Candidate Dx Gives More Labs A Chance To Test
This article was originally published in The Gray Sheet
Executive Summary
Invitrogen's SPOT-Light HER2 test, PMA-approved by FDA July 8, will not be the first kit in the U.S. to help physicians decide if a breast cancer patient will benefit from Genentech's Herceptin therapy, but it will allow a host of new laboratories to perform the analysis, according to the firm
You may also be interested in...
Invitrogen Herceptin candidate Dx launches
Firm taps Biocare Medical to distribute its SPOT-Light HER2 test. The kit was PMA approved July 8 for use as an aid to assess which breast cancer patients might benefit from treatment with Genentech's Herceptin therapy (1"The Gray Sheet" July 14, 2008, p. 17). "Working with the Biocare sales force, we believe we will be able to more rapidly and efficiently deliver this critical diagnostic," Invitrogen said
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.